Vtv Theraptcs Cl A (VTVT)

$31.68 -0.56 (-1.72%)
Market Cap 126.99M
Revenue (ttm) 0.00
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 33,600
Avg Vol 61,528
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 23%
Beta 0.40
Analysts Strong Sell
Price Target $53.33

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology
Sector: Healthcare
Phone: 336 841 0300
Fax: 336 841 0310
Address:
3980 Premier Drive, Suite 310, High Point, United States
BillionerOfKing
BillionerOfKing May. 1 at 4:14 AM
$VTVT Current Stock Price: $32.27
0 · Reply
dcajic2
dcajic2 Apr. 30 at 3:42 PM
$VTVT where did the interst go? Low volume. No news until at least July. Could be end of year before any news. I would be a buyer around $25
0 · Reply
dcajic2
dcajic2 Apr. 29 at 10:02 PM
$VTVT shorts working out once again. no news for many months. Why go long now?
0 · Reply
JohnWick0
JohnWick0 Apr. 29 at 6:51 PM
$VTVT A new player has entered the game and is currently loading … hope they have some exciting news to share next week 🔥🔥🔥
1 · Reply
dcajic2
dcajic2 Apr. 29 at 3:59 PM
$VTVT another short is working out. 3 to 8’months before any news drops. Under $25 is so possible
0 · Reply
dcajic2
dcajic2 Apr. 29 at 2:17 PM
$VTVT another short will work out again. Reality land. This management does not care one bit about shareholders. Very little news comes out of this company. No news is expected until second half of the year, no reason why this company is bullish yet.
0 · Reply
LongBallBarn
LongBallBarn Apr. 29 at 7:51 AM
$BNAI $AKAN $VTVT $EPOW
0 · Reply
JohnWick0
JohnWick0 Apr. 28 at 7:45 PM
$VTVT …news 🗞️ please 🙏 💸
0 · Reply
LongBallBarn
LongBallBarn Apr. 28 at 7:18 PM
$AKAN $HUMA $VTVT
1 · Reply
JohnWick0
JohnWick0 Apr. 28 at 1:57 PM
$VTVT It’s time to load 🔥🔥🔥
0 · Reply
Latest News on VTVT
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 7, 2026, 4:15 PM EDT - 24 days ago

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

Mar 16, 2026, 8:00 AM EDT - 6 weeks ago

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 4:01 PM EDT - 7 weeks ago

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

vTv Therapeutics to Participate in Upcoming Investor Conferences

Feb 13, 2026, 8:00 AM EST - 2 months ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

Feb 2, 2026, 8:00 AM EST - 3 months ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Dec 18, 2025, 4:05 PM EST - 4 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 4:15 PM EST - 6 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 7 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 15, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 4:57 PM EDT - 8 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Sep 2, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:15 PM EDT - 9 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 11, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Aug 7, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 11, 2025, 8:00 AM EDT - 11 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025, 9:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 1 year ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025, 12:00 PM EDT - 1 year ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 1:59 PM EDT - 1 year ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

Jun 24, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 28, 2024, 8:00 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

May 9, 2024, 4:51 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 16, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Jun 15, 2023, 7:33 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 24, 2023, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 5:56 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

BillionerOfKing
BillionerOfKing May. 1 at 4:14 AM
$VTVT Current Stock Price: $32.27
0 · Reply
dcajic2
dcajic2 Apr. 30 at 3:42 PM
$VTVT where did the interst go? Low volume. No news until at least July. Could be end of year before any news. I would be a buyer around $25
0 · Reply
dcajic2
dcajic2 Apr. 29 at 10:02 PM
$VTVT shorts working out once again. no news for many months. Why go long now?
0 · Reply
JohnWick0
JohnWick0 Apr. 29 at 6:51 PM
$VTVT A new player has entered the game and is currently loading … hope they have some exciting news to share next week 🔥🔥🔥
1 · Reply
dcajic2
dcajic2 Apr. 29 at 3:59 PM
$VTVT another short is working out. 3 to 8’months before any news drops. Under $25 is so possible
0 · Reply
dcajic2
dcajic2 Apr. 29 at 2:17 PM
$VTVT another short will work out again. Reality land. This management does not care one bit about shareholders. Very little news comes out of this company. No news is expected until second half of the year, no reason why this company is bullish yet.
0 · Reply
LongBallBarn
LongBallBarn Apr. 29 at 7:51 AM
$BNAI $AKAN $VTVT $EPOW
0 · Reply
JohnWick0
JohnWick0 Apr. 28 at 7:45 PM
$VTVT …news 🗞️ please 🙏 💸
0 · Reply
LongBallBarn
LongBallBarn Apr. 28 at 7:18 PM
$AKAN $HUMA $VTVT
1 · Reply
JohnWick0
JohnWick0 Apr. 28 at 1:57 PM
$VTVT It’s time to load 🔥🔥🔥
0 · Reply
km1663
km1663 Apr. 27 at 10:00 PM
$VTVT Feb 3-6 we had a similar move from 40.00 to 29. No worries, Waiting for some real news.
0 · Reply
dcajic2
dcajic2 Apr. 27 at 7:13 PM
$VTVT Love the short. Who called it under $30
0 · Reply
GDS_investing
GDS_investing Apr. 27 at 6:24 PM
$VTVT awesome
0 · Reply
Newtrader_covid19
Newtrader_covid19 Apr. 27 at 5:41 PM
$VTVT is some institutional investors unloading? How come it dropped from $40 to $30 so quickly? Is there any news?
0 · Reply
dcajic2
dcajic2 Apr. 24 at 6:59 PM
$VTVT who exactly has been buying this stock? Makes zero sense.
0 · Reply
dcajic2
dcajic2 Apr. 24 at 6:58 PM
$VTVT Many people Dumping today??
0 · Reply
dcajic2
dcajic2 Apr. 24 at 2:36 PM
$VTVT it would seem like such a manipulated stock. 7 times now in a year gets over $40 with no news and then gets knocked down each and every time.
0 · Reply
dcajic2
dcajic2 Apr. 24 at 2:35 PM
$VTVT short works out perfectly.
0 · Reply
LongBallBarn
LongBallBarn Apr. 24 at 11:30 AM
$OGN $VTVT $EPOW $IMNN Huge adds huge gains
0 · Reply
dcajic2
dcajic2 Apr. 23 at 6:18 PM
$VTVT should get closer to $30. No news for many months.
0 · Reply
zlotis
zlotis Apr. 23 at 5:39 PM
$VTVT WTF? Yesterday's spike was nice, but today, 10% drop is brutal. Any news?
2 · Reply
dcajic2
dcajic2 Apr. 23 at 2:55 PM
$VTVT I cannot be the only one that’s shorted all big pops.
0 · Reply